Össur hf
Market Cap
US$21.2b
Last Updated
2019/09/21 00:17 UTC
Data Sources
Company Financials +
Executive Summary
Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific.
Snowflake
Fundamentals
Proven track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Össur hf's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
11.4%
OSSF.F
1.1%
US Medical Equipment
-0.6%
US Market
1 Year Return
74.1%
OSSF.F
9.9%
US Medical Equipment
0.6%
US Market
OSSF.F outperformed the Medical Equipment industry which returned 9.5% over the past year.
OSSF.F outperformed the Market in United States of America which returned 1.1% over the past year.
Share holder returns
| OSSF.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.4% | 1.1% | -0.6% |
| 30 Day | 18.9% | 0.6% | 2.2% |
| 90 Day | n/a | 2.9% | 1.1% |
| 1 Year | 74.1%74.1% | 10.8%9.9% | 2.9%0.6% |
| 3 Year | 103.1%103.1% | 70.1%64.9% | 44.6%35.2% |
| 5 Year | n/a | 138.9%111.8% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Össur hf's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Össur hf undervalued based on future cash flows and its price relative to the stock market?
36.03x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Össur hf's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Össur hf's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Össur hf is good value based on earnings compared to the US Medical Equipment industry average.
Össur hf is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Össur hf is poor value based on expected growth next year.
Price Based on Value of Assets
Össur hf is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Össur hf expected to perform in the next 1 to 3 years based on estimates from 3 analysts?
12.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Össur hf's revenue is expected to grow by 6.8% yearly, however this is not considered high growth (20% yearly).
Össur hf's earnings are expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
Össur hf's revenue growth is positive but not above the United States of America market average.
Össur hf's earnings growth is positive but not above the United States of America market average.
Össur hf's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Össur hf is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Össur hf performed over the past 5 years?
7.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Össur hf's year on year earnings growth rate has been positive over the past 5 years.
Össur hf's 1-year earnings growth exceeds its 5-year average (32.5% vs 7.6%)
Össur hf's earnings growth has exceeded the US Medical Equipment industry average in the past year (32.5% vs 28.2%).
Return on Equity
Össur hf has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Össur hf used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Össur hf's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Össur hf's financial position?
Financial Position Analysis
Össur hf is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Össur hf's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Össur hf's level of debt (40.8%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (30.1% vs 40.8% today).
Debt is well covered by operating cash flow (37.4%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 17.6x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.2x debt.
Next Steps
Dividend
What is Össur hf's current dividend yield, its reliability and sustainability?
0.39%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Össur hf's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).
Össur hf's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).
Össur hf is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Össur hf is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Össur hf's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
No need to calculate the sustainability of Össur hf's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Össur hf's salary, the management and board of directors tenure and is there insider trading?
5.0yrs
Average management tenure
CEO
Jón Sigurdsson (63yo)
23.7yrs
Tenure
US$2,062,000
Compensation
Mr. Jón Sigurdsson has been the Chief Executive Officer and President of Gibaud SAS since 1996. Mr. Sigurdsson has been Senior Vice President of Procurement at Promens Canada Inc. and Promens hf. since Jul ...
CEO Compensation Analysis
Jón's remuneration is lower than average for companies of similar size in United States of America.
Jón's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
5.0yrs
Average Tenure
50yo
Average Age
The tenure for the Össur hf management team is about average.
Board Age and Tenure
10.7yrs
Average Tenure
62yo
Average Age
The average tenure for the Össur hf board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Jón Sigurdsson (63yo)
CEO & President
- Tenure: 23.7yrs
- Compensation: US$2.06m
Ossur Kristinsson (76yo)
- Tenure: 0yrs
- Compensation: US$25.00k
Egill Jónsson (62yo)
Executive Vice President of Manufacturing & Operations
- Tenure: 0yrs
- Compensation: US$444.00k
Ólafur Gylfason (50yo)
Executive Vice President of Sales & Marketing
- Tenure: 3.6yrs
- Compensation: US$600.00k
Sigurborg Arnarsdottir
Compliance Officer
- Tenure: 17.7yrs
Sveinn Sölvason (41yo)
Chief Financial Officer
- Tenure: 6.3yrs
- Compensation: US$221.00k
Margrét Friðriksdóttir (41yo)
Executive Vice President of Human Resources & Corporate Strategy
- Tenure: 0yrs
- Compensation: US$242.00k
Kim de Roy (42yo)
Executive Vice President of Research & Development
- Tenure: 1.8yrs
Gudjon Karason (50yo)
Executive Vice President of Clinics
- Tenure: 1.8yrs
David Hreidarsson
Investor Relations Manager
- Tenure: 0yrs
Board Members
Niels Jacobsen (62yo)
Chairman of the Board
- Tenure: 13.7yrs
- Compensation: US$94.00k
Kristján Ragnarsson (76yo)
Vice Chairman
- Tenure: 7.5yrs
- Compensation: US$56.00k
Svafa Grönfeldt (54yo)
Director
- Tenure: 11.7yrs
- Compensation: US$38.00k
Guðbjörg Eggertsdóttir (68yo)
Director
- Tenure: 6.5yrs
- Compensation: US$38.00k
Arne Nielsen (51yo)
Director
- Tenure: 10.7yrs
- Compensation: US$38.00k
Company Information
Össur hf.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Össur hf.
- Ticker: OSSF.F
- Exchange: OTCPK
- Founded: 1971
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: ø21.237b
- Listing Market Cap: ø3.129b
- Shares outstanding: 423.04m
- Website: https://www.ossur.com
Number of Employees
Location
- Össur hf.
- Grjothals 1 - 5
- Reykjavik
- 110
- Iceland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 0FIW | LSE (London Stock Exchange) | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSR | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Common Stock | DK | DKK | Oct 1999 |
| OSSRC | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | DKK | Oct 1999 |
| OSSF.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Oct 1999 |
| OSSU.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Dec 2011 |
Biography
Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. The company’s prosthetics p ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/21 00:17 |
| End of Day Share Price | 2019/09/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.